DUAVEE® Indications and Usage

(conjugated estrogens/bazedoxifene)

1 INDICATIONS AND USAGE

DUAVEE is indicated in women with a uterus for:

1.1 Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

1.2 Prevention of Postmenopausal Osteoporosis

1.3 Important Limitations of Use

•
Use DUAVEE for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
•
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.

Find DUAVEE® medical information:

Find DUAVEE® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

DUAVEE® Quick Finder

Medication Guide

Health Professional Information

Indications and Usage

1 INDICATIONS AND USAGE

DUAVEE is indicated in women with a uterus for:

1.1 Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

1.2 Prevention of Postmenopausal Osteoporosis

1.3 Important Limitations of Use

•
Use DUAVEE for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
•
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.
Prescribing Information
Download Prescribing Information

Health Professional Information

Indications and Usage

1 INDICATIONS AND USAGE

DUAVEE is indicated in women with a uterus for:

1.1 Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

1.2 Prevention of Postmenopausal Osteoporosis

1.3 Important Limitations of Use

•
Use DUAVEE for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
•
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information.9AM-5PM ET Monday to Friday; excluding holidays.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.